NI201300119A - Uso del anticuerpo anti - cd19 inmunoconjugado con maitansinoide para el tratatamiento del síntoma tumores de células b. - Google Patents

Uso del anticuerpo anti - cd19 inmunoconjugado con maitansinoide para el tratatamiento del síntoma tumores de células b.

Info

Publication number
NI201300119A
NI201300119A NI201300119A NI201300119A NI201300119A NI 201300119 A NI201300119 A NI 201300119A NI 201300119 A NI201300119 A NI 201300119A NI 201300119 A NI201300119 A NI 201300119A NI 201300119 A NI201300119 A NI 201300119A
Authority
NI
Nicaragua
Prior art keywords
maitansinoid
immunoconjugated
symptoms
antibody
treatment
Prior art date
Application number
NI201300119A
Other languages
English (en)
Spanish (es)
Inventor
Morariu Rodica
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201300119(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NI201300119A publication Critical patent/NI201300119A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NI201300119A 2011-05-17 2013-11-12 Uso del anticuerpo anti - cd19 inmunoconjugado con maitansinoide para el tratatamiento del síntoma tumores de células b. NI201300119A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11290232A EP2524929A1 (en) 2011-05-17 2011-05-17 Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms

Publications (1)

Publication Number Publication Date
NI201300119A true NI201300119A (es) 2014-02-28

Family

ID=46085972

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300119A NI201300119A (es) 2011-05-17 2013-11-12 Uso del anticuerpo anti - cd19 inmunoconjugado con maitansinoide para el tratatamiento del síntoma tumores de células b.

Country Status (30)

Country Link
US (2) US9555126B2 (enExample)
EP (2) EP2524929A1 (enExample)
JP (4) JP6050328B2 (enExample)
KR (1) KR20140043388A (enExample)
CN (2) CN107007840A (enExample)
AR (1) AR086412A1 (enExample)
AU (3) AU2012258254B2 (enExample)
BR (1) BR112013029330A8 (enExample)
CA (1) CA2835738A1 (enExample)
CL (1) CL2013003272A1 (enExample)
CO (1) CO6821893A2 (enExample)
CR (1) CR20130593A (enExample)
DO (1) DOP2013000260A (enExample)
EA (1) EA028574B1 (enExample)
EC (1) ECSP13013084A (enExample)
GT (1) GT201300276A (enExample)
IL (3) IL229380B (enExample)
MA (1) MA35180B1 (enExample)
MX (1) MX347019B (enExample)
MY (1) MY163736A (enExample)
NI (1) NI201300119A (enExample)
PE (1) PE20141018A1 (enExample)
PH (2) PH12013502305A1 (enExample)
SG (2) SG10201609729VA (enExample)
TN (1) TN2013000468A1 (enExample)
TW (3) TWI601537B (enExample)
UA (1) UA114401C2 (enExample)
UY (1) UY34077A (enExample)
WO (1) WO2012156455A1 (enExample)
ZA (1) ZA201309400B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
ES2883191T3 (es) 2013-08-30 2021-12-07 Immunogen Inc Anticuerpos y ensayos para la detección del receptor 1 de folato
CN105837689B (zh) * 2015-01-13 2020-06-19 博生吉安科细胞技术有限公司 抗cd19单克隆抗体及其制备方法
WO2016180941A1 (en) * 2015-05-13 2016-11-17 Sanofi Liquid compositions for anti-cd19 antibody-drug conjugates
SMT201900647T1 (it) 2015-05-26 2020-01-14 Morphosys Ag Combinazione di un anticorpo anti-cd19 e un inibitore della tirosina chinasi di bruton e suoi usi
WO2017032679A1 (en) 2015-08-21 2017-03-02 Morphosys Ag Combinations and uses thereof
HK1255141A1 (zh) 2015-09-17 2019-08-09 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
JP2019501139A (ja) 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド 医薬製剤及びその使用
LT3916392T (lt) 2016-05-30 2024-08-26 Incyte Corporation Pacientų gydymo anti-cd19 terapinės naudos prognozavimo būdai
SG10201912369QA (en) 2016-06-27 2020-02-27 Morphosys Ag Anti-cd19 antibody formulations
AU2017348624B2 (en) 2016-10-28 2024-09-26 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
WO2018183494A1 (en) * 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
KR20190137151A (ko) * 2017-04-20 2019-12-10 에이디씨 테라퓨틱스 에스에이 병용 요법
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
EP3684820A4 (en) * 2017-09-21 2021-05-26 Wuxi Biologics (Cayman) Inc. NOVEL ANTI-CD19 ANTIBODIES
MX2020003144A (es) 2017-09-22 2020-07-28 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos cd3/cd19.
US11274121B2 (en) 2018-01-12 2022-03-15 Immunogen, Inc. Methods for antibody drug conjugation, purification, and formulation
HRP20231619T1 (hr) 2019-04-26 2024-04-26 Immunogen, Inc. Derivati kamptotecina
JP2022532519A (ja) 2019-05-03 2022-07-15 モルフォシス・アーゲー 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
TWI883067B (zh) 2019-10-31 2025-05-11 美商英塞特公司 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
IL292181A (en) 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
US20210147568A1 (en) * 2019-10-31 2021-05-20 Forty Seven, Inc. Anti-cd47 based treatment of blood cancer
CN110845617B (zh) * 2019-12-05 2021-07-09 常州费洛斯药业科技有限公司 针对cd19的全人源抗体或抗体片段、嵌合抗原受体及应用
US20230014026A1 (en) 2020-06-22 2023-01-19 Morphosys Ag Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
US20240262907A1 (en) 2020-10-06 2024-08-08 Xencor, Inc. Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
IL303384A (en) 2020-12-04 2023-08-01 Morphosys Ag Anti-CD19 combination therapy
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
AU2023326589A1 (en) 2022-08-17 2025-02-20 Incyte Corporation Therapy comprising anti-cd19 antibody and ezh2 modulators
WO2025087382A1 (zh) * 2023-10-26 2025-05-01 上海先博生物科技有限公司 靶向cd19的嵌合抗原受体的治疗用途
WO2025157132A1 (en) 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
EP1651162B1 (en) * 2003-05-20 2015-10-21 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
US8323653B2 (en) * 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN108727407B (zh) * 2009-02-05 2022-01-28 伊缪诺金公司 新型苯并二氮杂䓬衍生物
CA2761120A1 (en) * 2009-05-06 2010-11-11 Biotest Ag Uses of immunoconjugates targeting cd138
WO2011050180A1 (en) * 2009-10-21 2011-04-28 Immunogen, Inc. Novel dosing regimen and method of treatment
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2550975A1 (en) * 2011-07-29 2013-01-30 Sanofi Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab

Also Published As

Publication number Publication date
JP2019142961A (ja) 2019-08-29
US9555126B2 (en) 2017-01-31
JP2017081926A (ja) 2017-05-18
UA114401C2 (uk) 2017-06-12
AR086412A1 (es) 2013-12-11
MY163736A (en) 2017-10-31
AU2012258254A1 (en) 2013-05-02
US20140072587A1 (en) 2014-03-13
IL257475A (en) 2018-06-28
PH12013502305A1 (en) 2019-07-03
MX2013013455A (es) 2014-02-17
CR20130593A (es) 2014-01-09
IL229380B (en) 2018-02-28
EA201391714A1 (ru) 2014-03-31
ECSP13013084A (es) 2014-01-31
DOP2013000260A (es) 2014-01-31
IL263728A (en) 2019-01-31
AU2012258254B2 (en) 2016-04-21
MX347019B (es) 2017-04-07
EP2710034A1 (en) 2014-03-26
TWI601537B (zh) 2017-10-11
JP2014515036A (ja) 2014-06-26
MA35180B1 (fr) 2014-06-02
US20170196988A1 (en) 2017-07-13
PE20141018A1 (es) 2014-08-27
IL229380A0 (en) 2014-01-30
CN107007840A (zh) 2017-08-04
JP6181273B2 (ja) 2017-08-16
JP2018021020A (ja) 2018-02-08
GT201300276A (es) 2015-03-23
AU2016206317A1 (en) 2016-08-11
AU2018201504A1 (en) 2018-03-22
CN103547596A (zh) 2014-01-29
UY34077A (es) 2013-01-03
TW201834687A (zh) 2018-10-01
EP2524929A1 (en) 2012-11-21
TW201249460A (en) 2012-12-16
CO6821893A2 (es) 2013-12-31
BR112013029330A2 (pt) 2016-11-29
SG10201609729VA (en) 2016-12-29
NZ618012A (en) 2016-03-31
BR112013029330A8 (pt) 2018-01-30
TN2013000468A1 (en) 2015-03-30
CL2013003272A1 (es) 2014-08-01
WO2012156455A1 (en) 2012-11-22
PH12017501368A1 (en) 2018-01-29
KR20140043388A (ko) 2014-04-09
SG194894A1 (en) 2013-12-30
ZA201309400B (en) 2015-04-29
EA028574B1 (ru) 2017-12-29
JP6050328B2 (ja) 2016-12-21
CA2835738A1 (en) 2012-11-22
TW201726167A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
NI201300119A (es) Uso del anticuerpo anti - cd19 inmunoconjugado con maitansinoide para el tratatamiento del síntoma tumores de células b.
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
MX379396B (es) Conjugados de pirrolobenzodiazepina y anticuerpo.
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
ECSP10010438A (es) ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS Y METODOS DE USO
EA201791843A3 (ru) Способы повышения эффективности folr1 терапии рака
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
MX2021013336A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
CL2011000931A1 (es) Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.
MX2015013194A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 humanizado.
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
EA201300530A1 (ru) Антитела к il-23
MX351975B (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
CR20110558A (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS Y MÉTODOS DE USO
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
BR112015025709A2 (pt) monoterapia com gla para uso em tratamento de câncer
CR20110553A (es) Terapia complementaria contra el cáncer
BR112015013260A2 (pt) uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
MX2014000066A (es) Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana.
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
CR10996A (es) Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana
EA201490938A1 (ru) Производные спиротиенопиранпиперидина в качестве антагонистов рецептора orl-1 для применения для лечения алкогольной зависимости и злоупотребления алкоголем
UY31449A1 (es) Propagacion de ortomixoviridae
UA104460C2 (uk) АНТИТІЛА ДО FсRCH5, ЇХ ІМУНОКОН'ЮГАТИ Й СПОСОБИ ЇХНЬОГО ЗАСТОСУВАННЯ